In this podcast Dr Hasib Sidiqi talks to the OPTIMISMM lead author, Professor Paul Richardson, about his views on treatment sequencing.

The OPTIMISMM trial showed that patients with relapsed or refractory multiple myeloma who had previously received lenalidomide had significantly improved progression free survival when treated with triplet pomalidomide, bortezomib and dexamethasone, compared to those who received bortezomib and dexamethasone.

Prof Richardson is Director of Clinical Research/Clinical Program Leader at the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and RJ Corman Professor of Medicine, Harvard Medical School

Dr Hasib Sidiqi is Consultant Haematologist at Fiona Stanley Hospital

Disclosure

This podcast was sponsored by Bristol-Myers Squibb. Any views expressed are those of the experts alone and do not necessarily reflect the views of the sponsor. Before prescribing, please review the Pomalyst product information via the TGA website. Treatment decisions based on information in this podcast are the responsibility of the prescribing physician.